Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) insider Barry Ticho sold 4,504 shares of Stoke Therapeutics stock in a transaction on Friday, August 1st. The shares were sold at an average price of $12.82, for a total transaction of $57,741.28. Following the transaction, the insider owned 16,775 shares in the company, valued at $215,055.50. The trade was a 21.17% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Barry Ticho also recently made the following trade(s):
- On Tuesday, June 3rd, Barry Ticho sold 6,471 shares of Stoke Therapeutics stock. The shares were sold at an average price of $10.03, for a total transaction of $64,904.13.
- On Monday, June 2nd, Barry Ticho sold 1,745 shares of Stoke Therapeutics stock. The shares were sold at an average price of $10.00, for a total transaction of $17,450.00.
Stoke Therapeutics Stock Performance
Shares of Stoke Therapeutics stock traded down $0.15 during trading on Friday, reaching $13.10. The company had a trading volume of 385,342 shares, compared to its average volume of 775,170. The company has a market cap of $715.26 million, a price-to-earnings ratio of 16.58 and a beta of 1.15. The firm's fifty day moving average is $12.05 and its 200-day moving average is $9.97. Stoke Therapeutics, Inc. has a fifty-two week low of $5.35 and a fifty-two week high of $16.15.
Institutional Investors Weigh In On Stoke Therapeutics
A number of institutional investors have recently modified their holdings of STOK. GAMMA Investing LLC raised its stake in shares of Stoke Therapeutics by 1,842.0% in the 1st quarter. GAMMA Investing LLC now owns 5,360 shares of the company's stock valued at $36,000 after purchasing an additional 5,084 shares in the last quarter. KLP Kapitalforvaltning AS bought a new stake in shares of Stoke Therapeutics during the 4th quarter valued at about $63,000. AlphaQuest LLC bought a new position in Stoke Therapeutics in the first quarter worth about $72,000. US Bancorp DE lifted its holdings in Stoke Therapeutics by 9,743.9% in the first quarter. US Bancorp DE now owns 11,222 shares of the company's stock worth $75,000 after acquiring an additional 11,108 shares during the last quarter. Finally, Fox Run Management L.L.C. bought a new position in Stoke Therapeutics in the first quarter worth about $92,000.
Wall Street Analysts Forecast Growth
A number of brokerages have commented on STOK. Jefferies Financial Group began coverage on shares of Stoke Therapeutics in a report on Friday, July 18th. They issued a "buy" rating and a $30.00 price objective on the stock. Needham & Company LLC reiterated a "buy" rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a report on Tuesday, July 1st. HC Wainwright cut their price objective on shares of Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating on the stock in a report on Wednesday, May 14th. Finally, Cantor Fitzgerald upgraded shares of Stoke Therapeutics to a "strong-buy" rating in a report on Wednesday, May 14th. Five analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, Stoke Therapeutics presently has a consensus rating of "Buy" and an average target price of $25.80.
View Our Latest Stock Report on STOK
About Stoke Therapeutics
(
Get Free Report)
Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.
See Also
Before you consider Stoke Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stoke Therapeutics wasn't on the list.
While Stoke Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
